Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Breast Neoplasms 2046Neoplasms 1460Carcinoma, Non-Small-Cell Lung 1363Prostatic Neoplasms 1106Multiple Myeloma 872Leukemia, Myeloid, Acute 772Colorectal Neoplasms 713Neoplasm Metastasis 704Lung Neoplasms 697Melanoma 688Lymphoma 666Leukemia 596Lymphoma, Non-Hodgkin 593Leukemia, Lymphocytic, Chronic, B-Cell 535Ovarian Neoplasms 535Pancreatic Neoplasms 500Precursor Cell Lymphoblastic Leukemia-Lymphoma 485Recurrence 474Myelodysplastic Syndromes 425Lymphoma, Follicular 418Carcinoma, Renal Cell 412Head and Neck Neoplasms 408Glioblastoma 380Lymphoma, Large B-Cell, Diffuse 379Brain Neoplasms 376Hodgkin Disease 354Carcinoma, Hepatocellular 333Squamous Cell Carcinoma of Head and Neck 326Lymphoma, Mantle-Cell 306Sarcoma 286

Interventions

Erlotinib Hydrochloride 1Botulinum Toxins, Type A 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Hereditary leiomyomatosis and renal cell cancer × Clear all
NCT01130519 2025-02-21

A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
83 enrolled 17 charts
Genitourinary

Hereditary leiomyomatosis and renal cell cancer, Carcinoma, Renal Cell, Kidney Neoplasms

NCT00971620 2017-04-07

Randomized Pilot Study for the Treatment of Cutaneous Leiomyomas With Botulinum Toxin

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
18 enrolled 22 charts
Genitourinary

Hereditary leiomyomatosis and renal cell cancer, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡